Major Depressive Disorder

🏷

Classifications

Harrison's Chapter

◆

Subtypes

5

Melancholic Depression

Characterized by anhedonia, psychomotor changes, and diurnal variation.

Atypical Depression

Features mood reactivity, hypersomnia, hyperphagia, and rejection sensitivity.

Psychotic Depression

Depression with hallucinations or delusions.

Seasonal Affective Disorder

Depression recurring in winter months.

Peripartum Depression

Depression during pregnancy or postpartum period.

?

Discussions and Knowledge Gaps

2

Excitation-inhibition (E/I) imbalance in prefrontal-cingulate cortices is implicated in MDD pathophysiology, but what are the molecular substrates underlying E/I dysregulation in depression? Are GABAergic, glutamatergic, serotonergic, and opioidergic systems dysregulated primarily (upstream drivers) or secondarily (consequences of other pathophysiology)? How do these neurochemical systems interact to produce measurable E/I imbalance?

KNOWLEDGE GAP OPEN gap_mdd_excitation_inhibition_imbalance_substrates

Attached to

pathophysiology#Excitation-Inhibition Imbalance pathophysiology#Monoamine Deficiency pathophysiology#Neuroplasticity Deficits

Recent neuroimaging studies (Ge et al., 2026) demonstrate that MDD patients show significantly reduced Hurst exponent values (a biophysically confirmed proxy of cortical E/I balance) in parietal and prefrontal-cingulate cortices, with transcriptomic enrichment for neuronal structural organization and mitochondrial function. Neurochemical mapping links E/I dysregulation to GABAergic, opioidergic, serotonergic, and synaptic density distributions. However, critical gaps remain: (1) the causal direction of E/I imbalance relative to monoamine deficiency and HPA-axis dysregulation; (2) whether specific GABA receptor subtypes (α1-α6, β1-β3, γ1-γ3) or glutamate receptor classes (NMDA, AMPA, kainate) are preferentially dysregulated in depression; (3) the role of parvalbumin-positive fast-spiking interneurons and other inhibitory circuits in producing cortical E/I imbalance; and (4) how ketamine's rapid antidepressant effects via NMDA-receptor antagonism mechanistically relate to E/I normalization in treatment-resistant depression. Understanding these substrates could identify new therapeutic targets distinct from monoamine reuptake inhibition.

Proposed experiments

Map GABA and glutamate receptor subtype dysregulation across cortical regions in MDD

postmortem brain tissue analysis

exp_mdd_ei_substrate_specificity

Using postmortem brain tissue from MDD and control subjects, perform multi-region quantification of GABA receptor subtype expression (α1-α6, β1-β3, γ1-γ3) and glutamate receptor class expression (GluN1/GluN2, GluA1-A4, GluK1-K5) via Western blot, qPCR, and in situ hybridization in prefrontal-cingulate cortices. Correlate subtype-specific changes with lifetime depression severity and antidepressant medication history.

Determine whether parvalbumin-positive interneuron dysfunction drives cortical E/I imbalance in depression models

in vivo electrophysiology and optogenetics

exp_mdd_ei_interneuron_circuits

In chronic-stress depression models and acute-stress models, use electrophysiology and optogenetics to measure inhibitory tone from parvalbumin-positive fast-spiking interneurons onto pyramidal neurons. Assess whether targeted optogenetic reactivation of inhibitory circuits restores cortical E/I balance and reverses depression-like behavior. Parallel human studies using MEG/EEG to measure cortical oscillatory power and phase-amplitude coupling as surrogates of interneuron function.

Test whether ketamine's rapid antidepressant effect requires cortical E/I rebalancing

in vivo neuroimaging and electrophysiology during pharmacological intervention

exp_mdd_ketamine_ei_restoration

In acute-stress depression models, measure time-resolved Hurst exponent and cortical E/I balance before, during (minutes to hours), and after ketamine administration. Assess whether E/I normalization precedes or follows behavioral antidepressant effects. Simultaneously measure monoamine levels and HPA-axis markers to determine temporal ordering and mechanistic independence of E/I rebalancing from classical monoamine pathways.

Show evidence (2 references)

PMID:42372880 SUPPORT Human Clinical

"Transcriptomic analysis identified enrichment for neuronal structural organization, nucleic acid metabolism, and mitochondrial function, with preferential overlap with excitatory and inhibitory neuron-specific gene sets."

Multimodal evidence links E/I dysregulation to transcriptomic changes in neuronal structure and energy metabolism, supporting the mechanistic relevance of this imbalance in MDD.

PMID:42372880 SUPPORT Human Clinical

"Divergent group-by-treatment effects were observed in the anterior cingulate and medial prefrontal cortices, with ketamine-induced increases in TRD patients."

The differential effect of ketamine on cortical E/I balance in treatment-resistant depression suggests E/I normalization as a putative mechanism underlying rapid antidepressant action, but the molecular pathway from NMDA antagonism to E/I balance restoration remains unresolved.

Emerging evidence implicates oligodendrocyte (OL) dysfunction and myelin abnormalities in major depressive disorder, extending beyond classical myelination to neural plasticity, neuronal metabolic support, and circuit regulation. Is OL/white-matter pathology a primary driver of MDD, or a secondary consequence of neuroinflammation, chronic stress, and HPA-axis hyperactivity? Which OL subsets and brain regions are most mechanistically relevant, and how does OL-astrocyte-microglia crosstalk causally link to depressive symptoms?

KNOWLEDGE GAP OPEN gap_mdd_oligodendrocyte_dysfunction

Attached to

pathophysiology#Oligodendrocyte Dysfunction and Demyelination pathophysiology#Neuroplasticity Deficits pathophysiology#Neuroinflammation pathophysiology#HPA Axis Dysregulation

Neuroimaging consistently shows white-matter and brain-connectivity alterations in MDD, and post-mortem and animal studies report reduced oligodendrocyte density, downregulated myelin-related genes, and myelin abnormalities. The Gan et al. (2026) review argues that OL dysfunction is a key pathophysiological mechanism in MDD that extends beyond myelination to include contributions to neural plasticity, metabolic support, and circuit regulation, manifesting primarily as myelin abnormalities tied to altered connectivity and emotional processing. What remains unresolved is the causal direction: whether OL/myelin pathology initiates circuit dysfunction and depressive symptoms, or whether it is downstream of neuroinflammation, glucocorticoid excess from HPA-axis hyperactivity, and impaired neuroplasticity. The relative importance of distinct OL populations (mature OLs vs. oligodendrocyte precursor cells) and region-specific contributions (prefrontal cortex vs. hippocampus) is also unknown. Because OLs interact bidirectionally with neurons, astrocytes, and microglia, disentangling OL-glial crosstalk from primary inflammatory signaling is difficult with cross-sectional human data. Resolving these questions would clarify whether remyelination-promoting or OL-protective strategies could serve as disease-modifying treatments rather than symptomatic ones.

Proposed experiments

Region-specific oligodendrocyte manipulation with longitudinal connectivity and behavioral readouts

cell-type-specific perturbation with longitudinal imaging and behavioral phenotyping

exp_mdd_ol_causality_remyelination

In a chronic-stress rodent model of depression, use cell-type-specific genetic and pharmacological tools to (a) deplete or impair mature oligodendrocytes and oligodendrocyte precursor cells in prefrontal cortex versus hippocampus, and (b) conversely promote remyelination, while measuring myelin integrity, neuroinflammatory glial activation, neural circuit connectivity, and depression-like behavior. Pair with a human cohort combining diffusion-MRI white-matter metrics, peripheral inflammatory markers, and longitudinal symptom trajectories to test temporal ordering of white-matter change relative to inflammation and symptom onset.

Readouts

Myelin integrity and white-matter connectivity

pathophysiology#Neuroplasticity Deficits

Quantify myelin sheath thickness, oligodendrocyte density, and white-matter tract connectivity (diffusion imaging) to test whether manipulating OL/myelin alters circuit structure independent of inflammation.

diffusion tensor imaging myelin histopathology

Direction: NEGATIVE

Glial neuroinflammatory activation

pathophysiology#Neuroinflammation

Measure microglial and astrocyte activation and proinflammatory cytokine levels to determine whether OL dysfunction precedes or follows neuroinflammatory signaling.

glial activation immunostaining cytokine quantification

Direction: POSITIVE

Depression-like behavior and symptom trajectory

pathophysiology#HPA Axis Dysregulation

Assess depression-like behavior in animals and longitudinal depressive symptom severity in humans relative to stress/glucocorticoid exposure to test whether OL-targeted intervention modifies outcome.

depression behavioral battery

Direction: NEGATIVE

Decision criterion

OL dysfunction is supported as a primary driver if region-specific OL depletion produces white-matter and depression-like phenotypes before or independent of neuroinflammatory activation, and if remyelination-promoting intervention reverses depressive behavior; it is supported as a secondary consequence if white-matter change consistently follows inflammatory and glucocorticoid signaling and OL manipulation alone does not alter depressive outcomes.

Would support

pathophysiology#Neuroplasticity Deficits pathophysiology#Neuroinflammation

Show evidence (2 references)

PMID:41730818 SUPPORT Other

"Emerging evidence increasingly implicates oligodendrocyte (OL) dysfunction as a key pathophysiological mechanism in MDD, extending beyond their classical role in myelination to include critical contributions to neural plasticity, metabolic support, and circuit regulation."

This review establishes OL dysfunction as an emerging mechanistic hypothesis in MDD that extends beyond myelination, motivating the knowledge gap about its role and causal position.

PMID:41730818 SUPPORT Other

"Finally, we highlight key knowledge gaps and propose future research directions aimed at clarifying the contribution of OL biology to depressive disorders and improving treatment outcomes."

The authors explicitly flag unresolved knowledge gaps and call for research clarifying the contribution of OL biology to depression, directly supporting this KNOWLEDGE_GAP entry.

⚙

Pathophysiology

8

Monoamine Deficiency

Reduced serotonin, norepinephrine, and dopamine neurotransmission in key brain circuits. While oversimplified, this remains a foundation for antidepressant pharmacotherapy.

Serotonergic Neuron CL:0000850 Dopaminergic Neuron CL:0000700 Noradrenergic Neuron CL:0008025

Serotonin Signaling GO:0007210 Dopamine Signaling GO:0007212

Show evidence (3 references)

PMID:38331979 SUPPORT

"The currently widely accepted theories of MDD pathogenesis include the neurotransmitter and receptor hypothesis, hypothalamic-pituitary-adrenal (HPA) axis hypothesis, cytokine hypothesis, neuroplasticity hypothesis and systemic influence hypothesis"

This review confirms the neurotransmitter hypothesis as a foundational theory of MDD pathogenesis, though it notes that multiple hypotheses are needed to fully explain the disorder.

PMID:39150594 SUPPORT

"MDD is especially burdensome as approved monoamine antidepressant treatments have weeks-long delays before clinical benefit and low remission rates."

This highlights the clinical reality of monoamine-based treatments, confirming their use while acknowledging their limitations in achieving remission.

PMID:38474387 SUPPORT

"neuroinflammation and gut dysbiosis induce alterations in tryptophan metabolism, culminating in decreased serotonin synthesis, impairments in neuroplasticity-related mechanisms, and glutamate-mediated excitotoxicity."

This demonstrates how inflammatory mechanisms contribute to decreased serotonin synthesis, supporting the monoamine deficiency theory while connecting it to broader pathophysiological processes.

Excitation-Inhibition Imbalance

Reduced cortex-wide excitation-inhibition (E/I) balance in prefrontal-cingulate cortices, reflecting dysregulation of GABAergic inhibitory and glutamatergic excitatory neurotransmission. E/I imbalance is implicated in depressive symptoms and ketamine treatment response in treatment-resistant depression.

GABAergic Neuron CL:0000617 Pyramidal Neuron CL:0000598

GABA Signaling GO:0007214 ↕ DYSREGULATED Glutamate Signaling GO:0007215 ↕ DYSREGULATED Synaptic Plasticity GO:0048167 ↕ DYSREGULATED

Show evidence (3 references)

PMID:42372880 SUPPORT Human Clinical

"Patients with MDD demonstrated significantly reduced Hurst exponent values, predominantly encompassing the parietal and prefrontal-cingulate cortices."

Neuroimaging biomarker showing reduced E/I balance in MDD-affected brain regions, using Hurst exponent as a biophysically confirmed proxy of E/I balance.

PMID:42372880 SUPPORT Human Clinical

"Neurochemically, Hurst exponent alterations were spatially associated with GABAergic, opioidergic, serotonergic, and synaptic density distributions."

Cortical E/I imbalance is spatially associated with specific neurochemical systems implicated in depression, including GABAergic, opioidergic, and serotonergic neurotransmission and synaptic density.

PMID:42372880 SUPPORT Human Clinical

"Divergent group-by-treatment effects were observed in the anterior cingulate and medial prefrontal cortices, with ketamine-induced increases in TRD patients."

Ketamine treatment increases cortical E/I balance in treatment-resistant depression, suggesting E/I normalization as a potential mechanism of rapid antidepressant action.

HPA Axis Dysregulation

Hyperactivity of the hypothalamic-pituitary-adrenal axis leads to elevated cortisol, which may contribute to hippocampal atrophy and cognitive symptoms.

Corticotroph CL:0002309

Cortisol Response GO:0071385

Show evidence (1 reference)

PMID:38331979 SUPPORT

"The currently widely accepted theories of MDD pathogenesis include the neurotransmitter and receptor hypothesis, hypothalamic-pituitary-adrenal (HPA) axis hypothesis, cytokine hypothesis, neuroplasticity hypothesis and systemic influence hypothesis"

This review identifies the HPA axis hypothesis as one of the widely accepted core pathophysiological mechanisms in MDD.

Neuroplasticity Deficits

Reduced BDNF and impaired synaptic plasticity in prefrontal cortex and hippocampus. Successful treatments restore neuroplasticity.

Neuron CL:0000540

Synaptic Plasticity GO:0048167

Show evidence (3 references)

PMID:38331979 SUPPORT

"The currently widely accepted theories of MDD pathogenesis include the neurotransmitter and receptor hypothesis, hypothalamic-pituitary-adrenal (HPA) axis hypothesis, cytokine hypothesis, neuroplasticity hypothesis and systemic influence hypothesis"

This comprehensive review identifies the neuroplasticity hypothesis as one of the core accepted mechanisms in MDD pathogenesis.

PMID:39150594 SUPPORT

"This narrative review provides a high-level overview of glutamate signaling in synaptogenesis and neural plasticity and the implications of glutamate dysregulation in depression."

This demonstrates the link between glutamate signaling, synaptogenesis, and neural plasticity deficits in depression, supporting the neuroplasticity deficit mechanism.

PMID:38474387 SUPPORT

"neuroinflammation and gut dysbiosis induce alterations in tryptophan metabolism, culminating in decreased serotonin synthesis, impairments in neuroplasticity-related mechanisms, and glutamate-mediated excitotoxicity."

This shows how inflammatory processes lead to impairments in neuroplasticity-related mechanisms, connecting inflammation to neuroplasticity deficits in MDD.

Neuroinflammation

Elevated inflammatory cytokines (IL-6, TNF-alpha, CRP) observed in depression. Inflammation may contribute to monoamine depletion and neuroplasticity deficits.

Microglia CL:0000129

Show evidence (4 references)

PMID:38331979 SUPPORT

"The currently widely accepted theories of MDD pathogenesis include the neurotransmitter and receptor hypothesis, hypothalamic-pituitary-adrenal (HPA) axis hypothesis, cytokine hypothesis, neuroplasticity hypothesis and systemic influence hypothesis"

This review identifies the cytokine hypothesis as one of the widely accepted theories of MDD pathogenesis, supporting the role of inflammatory mechanisms.

PMID:38474387 SUPPORT

"The involvement of central and peripheral inflammation in the pathogenesis and prognosis of major depressive disorder (MDD) has been demonstrated. The increase of pro-inflammatory cytokines (interleukin (IL)-1β, IL-6, IL-18, and TNF-α) in individuals with depression may elicit neuroinflammatory..."

This provides direct evidence for elevated pro-inflammatory cytokines in MDD and their role in eliciting neuroinflammatory processes.

PMID:38474387 SUPPORT

"mechanisms that, in turn, can contribute to gut microbiota dysbiosis. Together, neuroinflammation and gut dysbiosis induce alterations in tryptophan metabolism, culminating in decreased serotonin synthesis, impairments in neuroplasticity-related mechanisms, and glutamate-mediated excitotoxicity."

This demonstrates how neuroinflammation contributes to both monoamine depletion (decreased serotonin) and neuroplasticity deficits, confirming the description's mechanistic links.

+ 1 more reference

Mitochondrial Dysfunction

Impaired mitochondrial respiration and cellular energy metabolism contribute to MDD pathophysiology. Patient-derived cells show decreased mitochondrial function, altered membrane potential, and disrupted calcium homeostasis.

Show evidence (3 references)

PMID:38256041 SUPPORT

"The link between mitochondria and major depressive disorder (MDD) is increasingly evident, underscored both by mitochondria's involvement in many mechanisms identified in depression and the high prevalence of MDD in individuals with mitochondrial disorders."

This establishes the connection between mitochondrial dysfunction and MDD, noting both mechanistic involvement and epidemiological evidence.

PMID:38256041 SUPPORT

"Similarities were observed between the Mito patient and a broader MDD cohort, including decreased respiration and mitochondrial function."

This provides direct evidence from patient-derived cells showing decreased mitochondrial respiration and function in MDD patients.

PMID:38256041 SUPPORT

"the Non-R patient's data offered a new perspective on MDD, suggesting a detrimental imbalance in mitochondrial and cellular processes, rather than simply reduced functions."

This suggests that mitochondrial dysfunction in MDD may involve complex imbalances beyond simple reduction, including altered respiratory rates and calcium homeostasis.

Reference Point Dysregulation

Pathological elevation and inflexibility of the decisional reference point, a core mechanism from behavioral economics that determines how events are experienced as positive or negative. Elevated reference points cause previously rewarding activities to be experienced as aversive, contributing to anhedonia and reward dysfunction. Dysfunction in anterior cingulate cortex impairs dynamic adjustment of the reference point to environmental changes.

Neuron CL:0000540

Cognition GO:0050890

Show evidence (4 references)

PMID:42150067 SUPPORT

"A pathological elevation of the reference point would lead a person to experience once pleasurable activities as negative reinforcers."

This describes how pathological reference point elevation in MDD directly causes anhedonia by transforming reward into punishment.

PMID:42150067 SUPPORT

"depression is associated with a significant elevation of the reference point, and the magnitude of this elevation correlates with disease severity."

This provides direct evidence linking elevated reference points to depression severity in MDD patients.

PMID:42150067 SUPPORT

"The ability of patients with MDD to dynamically adjust their reference point to the environment is also dysfunctional."

This demonstrates that MDD patients show impaired cognitive flexibility in adapting reward valuation to environmental context.

+ 1 more reference

Oligodendrocyte Dysfunction and Demyelination

Oligodendrocyte (OL) dysfunction and myelin abnormalities contribute to depression pathophysiology through multiple mechanisms: impaired myelination reduces conduction velocity and disrupts neural circuit function; loss of OL-derived metabolic support decreases neuronal energy supply; compromised OL-glial crosstalk with microglia and astrocytes amplifies neuroinflammation. These dysfunctions are associated with altered brain connectivity and emotional processing deficits, and may represent a targetable node for therapeutic remyelination strategies.

Oligodendrocyte CL:0000128 Oligodendrocyte Precursor Cell CL:0002453 Neuron CL:0000540 Microglia CL:0000129 Astrocyte CL:0000127

Myelination GO:0042552 ↓ DECREASED Synaptic Plasticity GO:0048167 ↓ DECREASED Axon Ensheathment GO:0008366

Downstream

Neuroplasticity Deficits

Neuroinflammation

Show evidence (3 references)

PMID:41730818 SUPPORT Other

"Emerging evidence increasingly implicates oligodendrocyte (OL) dysfunction as a key pathophysiological mechanism in MDD, extending beyond their classical role in myelination to include critical contributions to neural plasticity, metabolic support, and circuit regulation."

This establishes OL dysfunction as a key pathophysiological mechanism in MDD that extends beyond myelination to encompass neural plasticity and metabolic support functions.

PMID:41730818 SUPPORT Other

"Such dysfunctions manifest primarily as myelin abnormalities and are closely associated with depression-related alterations in brain connectivity and emotional processing."

This demonstrates the functional consequences of OL dysfunction, linking myelin abnormalities to altered brain connectivity and emotional processing deficits central to depression.

PMID:41730818 SUPPORT Other

"with particular emphasis on their interactions with neurons, astrocytes, and microglia within the central nervous system"

This directly supports the OL-glial crosstalk mechanism described in this node, confirming that oligodendrocyte dysfunction involves disrupted interactions with astrocytes and microglia in MDD.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

7

Digestive 1

Poor Appetite FREQUENT Poor appetite HP:0004396

Decreased or increased appetite

Nervous System 5

Depressed Mood VERY_FREQUENT Depression HP:0000716

Anhedonia VERY_FREQUENT Anhedonia HP:0012154

Loss of interest or pleasure

Sleep Disturbance VERY_FREQUENT Sleep disturbance HP:0002360

Insomnia or hypersomnia

Concentration Difficulties FREQUENT Cognitive impairment HP:0100543

Psychomotor Changes OCCASIONAL Choreoathetosis HP:0001266

Retardation or agitation

Constitutional 1

Fatigue VERY_FREQUENT Fatigue HP:0012378

🧬

Genetic Associations

4

SLC6A4 (Risk Factor)

BDNF (Risk Factor)

FKBP5 (Risk Factor)

HTR2A (Risk Factor)

💊

Medical Actions

7

Selective Serotonin Reuptake Inhibitors (SSRIs)

First-line pharmacotherapy (sertraline, escitalopram, fluoxetine).

Show evidence (1 reference)

PMID:39150594 SUPPORT

"MDD is especially burdensome as approved monoamine antidepressant treatments have weeks-long delays before clinical benefit and low remission rates."

This confirms the clinical use of monoamine antidepressants while acknowledging their limitations in terms of delayed benefit and incomplete remission.

Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

Venlafaxine, duloxetine for depression with pain or fatigue.

Cognitive Behavioral Therapy

Evidence-based psychotherapy, comparable efficacy to medications.

Electroconvulsive Therapy

Most effective treatment for severe or treatment-resistant depression.

Ketamine/Esketamine

Rapid-acting treatment for treatment-resistant depression.

Show evidence (3 references)

PMID:39150594 SUPPORT

"Nasal administration of esketamine (Spravato®) was approved by the US Food and Drug Administration (FDA) in 2019 to treat adults with treatment-resistant depression and in 2020 for adults with MDD with acute suicidal ideation or behavior."

This confirms FDA approval of esketamine for treatment-resistant depression and acute suicidal ideation/behavior in MDD.

PMID:39150594 SUPPORT

"Based on this preclinical evidence implicating glutamate in depression and the rapid improvement of depression with ketamine treatment in a proof-of-concept trial, a range of N-methyl-D-aspartate (NMDA)-targeted therapies have been investigated."

This explains the mechanistic basis for ketamine's rapid-acting antidepressant effects through NMDA receptor antagonism and glutamate modulation.

PMID:39150594 SUPPORT

"Oral combination dextromethorphan-bupropion (AXS-05, Auvelity® extended-release tablet) was FDA approved in 2022 for the treatment of MDD in adults."

This documents the approval of another glutamatergic modulator for MDD treatment, expanding treatment options beyond esketamine.

Transcranial Magnetic Stimulation

Non-invasive neuromodulation for treatment-resistant depression.

Behavioral Activation

Increasing engagement in rewarding activities.

🌍

Environmental Factors

4

Childhood Trauma

Strong risk factor for adult depression

Chronic Stress

Major precipitant

Show evidence (1 reference)

PMID:38331979 SUPPORT

"The currently widely accepted theories of MDD pathogenesis include the neurotransmitter and receptor hypothesis, hypothalamic-pituitary-adrenal (HPA) axis hypothesis, cytokine hypothesis, neuroplasticity hypothesis and systemic influence hypothesis"

The HPA axis hypothesis directly relates to stress response dysregulation, supporting chronic stress as a major environmental precipitant of MDD.

Social Isolation

Risk factor and consequence

Substance Abuse

Bidirectional relationship

🔬

Biochemical Markers

3

Cortisol (Elevated)

Context: HPA axis hyperactivity

Show evidence (1 reference)

PMID:38331979 SUPPORT

"The currently widely accepted theories of MDD pathogenesis include the neurotransmitter and receptor hypothesis, hypothalamic-pituitary-adrenal (HPA) axis hypothesis, cytokine hypothesis, neuroplasticity hypothesis and systemic influence hypothesis"

The HPA axis hypothesis supports elevated cortisol as a key biochemical feature of MDD.

BDNF (Decreased)

Context: Reduced neuroplasticity marker

Show evidence (1 reference)

PMID:38474387 SUPPORT

"neuroinflammation and gut dysbiosis induce alterations in tryptophan metabolism, culminating in decreased serotonin synthesis, impairments in neuroplasticity-related mechanisms, and glutamate-mediated excitotoxicity."

This demonstrates how neuroplasticity-related mechanisms are impaired in MDD, which is consistent with decreased BDNF as a neuroplasticity marker.

Inflammatory Markers (Elevated)

Context: IL-6, CRP, TNF-alpha

Show evidence (1 reference)

PMID:38474387 SUPPORT

"The increase of pro-inflammatory cytokines (interleukin (IL)-1β, IL-6, IL-18, and TNF-α) in individuals with depression may elicit neuroinflammatory processes and peripheral inflammation"

This directly confirms elevated inflammatory cytokines including IL-6 and TNF-α in MDD patients.

{ }

Source YAML

click to show

name: Major Depressive Disorder
creation_date: '2025-12-18T17:01:35Z'
updated_date: '2026-02-17T21:53:14Z'
description: >-
  Major depressive disorder (MDD) is a common, often recurrent psychiatric mood
  disorder defined by persistent depressed mood and/or anhedonia accompanied by
  neurovegetative, cognitive, and somatic symptoms that impair functioning.
  Recognized clinical subtypes include melancholic, atypical, psychotic,
  seasonal, and peripartum depression. Pathophysiology implicates monoamine
  deficiency, hypothalamic-pituitary-adrenal axis dysregulation, neuroinflammation,
  and impaired neuroplasticity.
category: Complex
parents:
- Psychiatric Disease
- Mood Disorder
disease_term:
  preferred_term: major depressive disorder
  term:
    id: MONDO:0002009
    label: major depressive disorder
has_subtypes:
- name: Melancholic Depression
  description: Characterized by anhedonia, psychomotor changes, and diurnal
    variation.
- name: Atypical Depression
  description: Features mood reactivity, hypersomnia, hyperphagia, and rejection
    sensitivity.
- name: Psychotic Depression
  description: Depression with hallucinations or delusions.
- name: Seasonal Affective Disorder
  description: Depression recurring in winter months.
- name: Peripartum Depression
  description: Depression during pregnancy or postpartum period.
pathophysiology:
- name: Monoamine Deficiency
  description: >
    Reduced serotonin, norepinephrine, and dopamine neurotransmission in
    key brain circuits. While oversimplified, this remains a foundation
    for antidepressant pharmacotherapy.
  cell_types:
  - preferred_term: Serotonergic Neuron
    term:
      id: CL:0000850
      label: serotonergic neuron
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  - preferred_term: Noradrenergic Neuron
    term:
      id: CL:0008025
      label: noradrenergic neuron
  biological_processes:
  - preferred_term: Serotonin Signaling
    term:
      id: GO:0007210
      label: serotonin receptor signaling pathway
  - preferred_term: Dopamine Signaling
    term:
      id: GO:0007212
      label: G protein-coupled dopamine receptor signaling pathway
  evidence:
  - reference: PMID:38331979
    reference_title: "Major depressive disorder: hypothesis, mechanism, prevention and treatment."
    supports: SUPPORT
    snippet: "The currently widely accepted theories of MDD pathogenesis include the
      neurotransmitter and receptor hypothesis, hypothalamic-pituitary-adrenal (HPA)
      axis hypothesis, cytokine hypothesis, neuroplasticity hypothesis and systemic
      influence hypothesis"
    explanation: This review confirms the neurotransmitter hypothesis as a
      foundational theory of MDD pathogenesis, though it notes that multiple
      hypotheses are needed to fully explain the disorder.
  - reference: PMID:39150594
    reference_title: "Glutamatergic Modulators for Major Depression from Theory to Clinical Use."
    supports: SUPPORT
    snippet: "MDD is especially burdensome as approved monoamine antidepressant treatments
      have weeks-long delays before clinical benefit and low remission rates."
    explanation: This highlights the clinical reality of monoamine-based
      treatments, confirming their use while acknowledging their limitations in
      achieving remission.
  - reference: PMID:38474387
    reference_title: "Role of Inflammatory Mechanisms in Major Depressive Disorder: From Etiology to Potential Pharmacological Targets."
    supports: SUPPORT
    snippet: "neuroinflammation and gut dysbiosis induce alterations in tryptophan
      metabolism, culminating in decreased serotonin synthesis, impairments in neuroplasticity-related
      mechanisms, and glutamate-mediated excitotoxicity."
    explanation: This demonstrates how inflammatory mechanisms contribute to
      decreased serotonin synthesis, supporting the monoamine deficiency theory
      while connecting it to broader pathophysiological processes.
- name: Excitation-Inhibition Imbalance
  description: >
    Reduced cortex-wide excitation-inhibition (E/I) balance in prefrontal-cingulate
    cortices, reflecting dysregulation of GABAergic inhibitory and glutamatergic
    excitatory neurotransmission. E/I imbalance is implicated in depressive
    symptoms and ketamine treatment response in treatment-resistant depression.
  cell_types:
  - preferred_term: GABAergic Neuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  - preferred_term: Pyramidal Neuron
    description: Glutamatergic excitatory neurons
    term:
      id: CL:0000598
      label: pyramidal neuron
  biological_processes:
  - preferred_term: GABA Signaling
    term:
      id: GO:0007214
      label: gamma-aminobutyric acid signaling pathway
    modifier: DYSREGULATED
  - preferred_term: Glutamate Signaling
    term:
      id: GO:0007215
      label: glutamate receptor signaling pathway
    modifier: DYSREGULATED
  - preferred_term: Synaptic Plasticity
    term:
      id: GO:0048167
      label: regulation of synaptic plasticity
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:42372880
    reference_title: "Intrinsic excitation-inhibition imbalance in major depressive disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with MDD demonstrated significantly reduced Hurst exponent values, predominantly encompassing the parietal and prefrontal-cingulate cortices."
    explanation: Neuroimaging biomarker showing reduced E/I balance in MDD-affected brain regions, using Hurst exponent as a biophysically confirmed proxy of E/I balance.
  - reference: PMID:42372880
    reference_title: "Intrinsic excitation-inhibition imbalance in major depressive disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurochemically, Hurst exponent alterations were spatially associated with GABAergic, opioidergic, serotonergic, and synaptic density distributions."
    explanation: Cortical E/I imbalance is spatially associated with specific neurochemical systems implicated in depression, including GABAergic, opioidergic, and serotonergic neurotransmission and synaptic density.
  - reference: PMID:42372880
    reference_title: "Intrinsic excitation-inhibition imbalance in major depressive disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Divergent group-by-treatment effects were observed in the anterior cingulate and medial prefrontal cortices, with ketamine-induced increases in TRD patients."
    explanation: Ketamine treatment increases cortical E/I balance in treatment-resistant depression, suggesting E/I normalization as a potential mechanism of rapid antidepressant action.
- name: HPA Axis Dysregulation
  description: >
    Hyperactivity of the hypothalamic-pituitary-adrenal axis leads to
    elevated cortisol, which may contribute to hippocampal atrophy and
    cognitive symptoms.
  cell_types:
  - preferred_term: Corticotroph
    term:
      id: CL:0002309
      label: corticotroph
  biological_processes:
  - preferred_term: Cortisol Response
    term:
      id: GO:0071385
      label: cellular response to glucocorticoid stimulus
  evidence:
  - reference: PMID:38331979
    reference_title: "Major depressive disorder: hypothesis, mechanism, prevention and treatment."
    supports: SUPPORT
    snippet: "The currently widely accepted theories of MDD pathogenesis include the
      neurotransmitter and receptor hypothesis, hypothalamic-pituitary-adrenal (HPA)
      axis hypothesis, cytokine hypothesis, neuroplasticity hypothesis and systemic
      influence hypothesis"
    explanation: This review identifies the HPA axis hypothesis as one of the
      widely accepted core pathophysiological mechanisms in MDD.
- name: Neuroplasticity Deficits
  description: >
    Reduced BDNF and impaired synaptic plasticity in prefrontal cortex
    and hippocampus. Successful treatments restore neuroplasticity.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Synaptic Plasticity
    term:
      id: GO:0048167
      label: regulation of synaptic plasticity
  evidence:
  - reference: PMID:38331979
    reference_title: "Major depressive disorder: hypothesis, mechanism, prevention and treatment."
    supports: SUPPORT
    snippet: "The currently widely accepted theories of MDD pathogenesis include the
      neurotransmitter and receptor hypothesis, hypothalamic-pituitary-adrenal (HPA)
      axis hypothesis, cytokine hypothesis, neuroplasticity hypothesis and systemic
      influence hypothesis"
    explanation: This comprehensive review identifies the neuroplasticity
      hypothesis as one of the core accepted mechanisms in MDD pathogenesis.
  - reference: PMID:39150594
    reference_title: "Glutamatergic Modulators for Major Depression from Theory to Clinical Use."
    supports: SUPPORT
    snippet: "This narrative review provides a high-level overview of glutamate signaling
      in synaptogenesis and neural plasticity and the implications of glutamate dysregulation
      in depression."
    explanation: This demonstrates the link between glutamate signaling,
      synaptogenesis, and neural plasticity deficits in depression, supporting
      the neuroplasticity deficit mechanism.
  - reference: PMID:38474387
    reference_title: "Role of Inflammatory Mechanisms in Major Depressive Disorder: From Etiology to Potential Pharmacological Targets."
    supports: SUPPORT
    snippet: "neuroinflammation and gut dysbiosis induce alterations in tryptophan
      metabolism, culminating in decreased serotonin synthesis, impairments in neuroplasticity-related
      mechanisms, and glutamate-mediated excitotoxicity."
    explanation: This shows how inflammatory processes lead to impairments in
      neuroplasticity-related mechanisms, connecting inflammation to
      neuroplasticity deficits in MDD.
- name: Neuroinflammation
  description: >
    Elevated inflammatory cytokines (IL-6, TNF-alpha, CRP) observed in
    depression. Inflammation may contribute to monoamine depletion and
    neuroplasticity deficits.
  cell_types:
  - preferred_term: Microglia
    term:
      id: CL:0000129
      label: microglial cell
  evidence:
  - reference: PMID:38331979
    reference_title: "Major depressive disorder: hypothesis, mechanism, prevention and treatment."
    supports: SUPPORT
    snippet: "The currently widely accepted theories of MDD pathogenesis include the
      neurotransmitter and receptor hypothesis, hypothalamic-pituitary-adrenal (HPA)
      axis hypothesis, cytokine hypothesis, neuroplasticity hypothesis and systemic
      influence hypothesis"
    explanation: This review identifies the cytokine hypothesis as one of the
      widely accepted theories of MDD pathogenesis, supporting the role of
      inflammatory mechanisms.
  - reference: PMID:38474387
    reference_title: "Role of Inflammatory Mechanisms in Major Depressive Disorder: From Etiology to Potential Pharmacological Targets."
    supports: SUPPORT
    snippet: "The involvement of central and peripheral inflammation in the pathogenesis
      and prognosis of major depressive disorder (MDD) has been demonstrated. The
      increase of pro-inflammatory cytokines (interleukin (IL)-1β, IL-6, IL-18, and
      TNF-α) in individuals with depression may elicit neuroinflammatory processes
      and peripheral inflammation"
    explanation: This provides direct evidence for elevated pro-inflammatory
      cytokines in MDD and their role in eliciting neuroinflammatory processes.
  - reference: PMID:38474387
    reference_title: "Role of Inflammatory Mechanisms in Major Depressive Disorder: From Etiology to Potential Pharmacological Targets."
    supports: SUPPORT
    snippet: "mechanisms that, in turn, can contribute to gut microbiota dysbiosis.
      Together, neuroinflammation and gut dysbiosis induce alterations in tryptophan
      metabolism, culminating in decreased serotonin synthesis, impairments in neuroplasticity-related
      mechanisms, and glutamate-mediated excitotoxicity."
    explanation: This demonstrates how neuroinflammation contributes to both
      monoamine depletion (decreased serotonin) and neuroplasticity deficits,
      confirming the description's mechanistic links.
  - reference: PMID:20015486
    reference_title: "A meta-analysis of cytokines in major depression."
    supports: SUPPORT
    snippet: This meta-analysis reports significantly higher concentrations of
      the proinflammatory cytokines TNF-alpha and IL-6 in depressed subjects
      compared with control subjects.
    explanation: Meta-analysis evidence shows elevated proinflammatory cytokines
      in major depression, supporting neuroinflammatory mechanisms.
- name: Mitochondrial Dysfunction
  description: >
    Impaired mitochondrial respiration and cellular energy metabolism contribute to
    MDD pathophysiology. Patient-derived cells show decreased mitochondrial function,
    altered membrane potential, and disrupted calcium homeostasis.
  evidence:
  - reference: PMID:38256041
    reference_title: "Mitochondrial and Cellular Function in Fibroblasts, Induced Neurons, and Astrocytes Derived from Case Study Patients: Insights into Major Depression as a Mitochondria-Associated Disease."
    supports: SUPPORT
    snippet: "The link between mitochondria and major depressive disorder (MDD) is
      increasingly evident, underscored both by mitochondria's involvement in many
      mechanisms identified in depression and the high prevalence of MDD in individuals
      with mitochondrial disorders."
    explanation: This establishes the connection between mitochondrial
      dysfunction and MDD, noting both mechanistic involvement and
      epidemiological evidence.
  - reference: PMID:38256041
    reference_title: "Mitochondrial and Cellular Function in Fibroblasts, Induced Neurons, and Astrocytes Derived from Case Study Patients: Insights into Major Depression as a Mitochondria-Associated Disease."
    supports: SUPPORT
    snippet: "Similarities were observed between the Mito patient and a broader MDD
      cohort, including decreased respiration and mitochondrial function."
    explanation: This provides direct evidence from patient-derived cells
      showing decreased mitochondrial respiration and function in MDD patients.
  - reference: PMID:38256041
    reference_title: "Mitochondrial and Cellular Function in Fibroblasts, Induced Neurons, and Astrocytes Derived from Case Study Patients: Insights into Major Depression as a Mitochondria-Associated Disease."
    supports: SUPPORT
    snippet: "the Non-R patient's data offered a new perspective on MDD, suggesting
      a detrimental imbalance in mitochondrial and cellular processes, rather than
      simply reduced functions."
    explanation: This suggests that mitochondrial dysfunction in MDD may involve
      complex imbalances beyond simple reduction, including altered respiratory
      rates and calcium homeostasis.
- name: Reference Point Dysregulation
  description: >
    Pathological elevation and inflexibility of the decisional reference point,
    a core mechanism from behavioral economics that determines how events are
    experienced as positive or negative. Elevated reference points cause previously
    rewarding activities to be experienced as aversive, contributing to anhedonia
    and reward dysfunction. Dysfunction in anterior cingulate cortex impairs
    dynamic adjustment of the reference point to environmental changes.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Cognition
    term:
      id: GO:0050890
      label: cognition
  evidence:
  - reference: PMID:42150067
    reference_title: "Decisional reference point pathology: A cognitive mechanism for and a correlate of major depressive disorder in humans."
    supports: SUPPORT
    snippet: "A pathological elevation of the reference point would lead a person
      to experience once pleasurable activities as negative reinforcers."
    explanation: This describes how pathological reference point elevation in MDD
      directly causes anhedonia by transforming reward into punishment.
  - reference: PMID:42150067
    reference_title: "Decisional reference point pathology: A cognitive mechanism for and a correlate of major depressive disorder in humans."
    supports: SUPPORT
    snippet: "depression is associated with a significant elevation of the reference
      point, and the magnitude of this elevation correlates with disease severity."
    explanation: This provides direct evidence linking elevated reference points
      to depression severity in MDD patients.
  - reference: PMID:42150067
    reference_title: "Decisional reference point pathology: A cognitive mechanism for and a correlate of major depressive disorder in humans."
    supports: SUPPORT
    snippet: "The ability of patients with MDD to dynamically adjust their reference
      point to the environment is also dysfunctional."
    explanation: This demonstrates that MDD patients show impaired cognitive
      flexibility in adapting reward valuation to environmental context.
  - reference: PMID:42150067
    reference_title: "Decisional reference point pathology: A cognitive mechanism for and a correlate of major depressive disorder in humans."
    supports: SUPPORT
    snippet: "findings link the previously demonstrated treatment of depression by
      deep brain stimulation to modulation of the reference point in the anterior
      cingulate cortex"
    explanation: This connects reference point pathology to a known treatment
      mechanism (DBS), identifying anterior cingulate cortex as the key locus of
      this dysfunction.
- name: Oligodendrocyte Dysfunction and Demyelination
  description: >
    Oligodendrocyte (OL) dysfunction and myelin abnormalities contribute to
    depression pathophysiology through multiple mechanisms: impaired myelination
    reduces conduction velocity and disrupts neural circuit function; loss of
    OL-derived metabolic support decreases neuronal energy supply; compromised
    OL-glial crosstalk with microglia and astrocytes amplifies neuroinflammation.
    These dysfunctions are associated with altered brain connectivity and emotional
    processing deficits, and may represent a targetable node for therapeutic
    remyelination strategies.
  cell_types:
  - preferred_term: Oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  - preferred_term: Oligodendrocyte Precursor Cell
    term:
      id: CL:0002453
      label: oligodendrocyte precursor cell
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: Microglia
    term:
      id: CL:0000129
      label: microglial cell
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: Myelination
    term:
      id: GO:0042552
      label: myelination
    modifier: DECREASED
  - preferred_term: Synaptic Plasticity
    term:
      id: GO:0048167
      label: regulation of synaptic plasticity
    modifier: DECREASED
  - preferred_term: Axon Ensheathment
    term:
      id: GO:0008366
      label: axon ensheathment
  evidence:
  - reference: PMID:41730818
    reference_title: "Oligodendrocyte dysfunction in major depressive disorder: Mechanistic insights and emerging therapies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Emerging evidence increasingly implicates oligodendrocyte (OL) dysfunction
      as a key pathophysiological mechanism in MDD, extending beyond their classical
      role in myelination to include critical contributions to neural plasticity,
      metabolic support, and circuit regulation."
    explanation: This establishes OL dysfunction as a key pathophysiological
      mechanism in MDD that extends beyond myelination to encompass neural plasticity
      and metabolic support functions.
  - reference: PMID:41730818
    reference_title: "Oligodendrocyte dysfunction in major depressive disorder: Mechanistic insights and emerging therapies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Such dysfunctions manifest primarily as myelin abnormalities and are
      closely associated with depression-related alterations in brain connectivity
      and emotional processing."
    explanation: This demonstrates the functional consequences of OL dysfunction,
      linking myelin abnormalities to altered brain connectivity and emotional
      processing deficits central to depression.
  - reference: PMID:41730818
    reference_title: "Oligodendrocyte dysfunction in major depressive disorder: Mechanistic insights and emerging therapies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "with particular emphasis on their interactions with neurons, astrocytes,
      and microglia within the central nervous system"
    explanation: This directly supports the OL-glial crosstalk mechanism described
      in this node, confirming that oligodendrocyte dysfunction involves disrupted
      interactions with astrocytes and microglia in MDD.
  downstream:
  - target: Neuroplasticity Deficits
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - OL dysfunction and myelin abnormalities impair neural plasticity through
      loss of metabolic and trophic support to neurons.
  - target: Neuroinflammation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - OL-microglia and OL-astrocyte interactions link oligodendrocyte dysfunction
      to neuroinflammatory signaling in MDD.
phenotypes:
- name: Depressed Mood
  category: Psychiatric
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
- name: Anhedonia
  category: Psychiatric
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Loss of interest or pleasure
  phenotype_term:
    preferred_term: Anhedonia
    term:
      id: HP:0012154
      label: Anhedonia
- name: Sleep Disturbance
  category: Sleep
  frequency: VERY_FREQUENT
  notes: Insomnia or hypersomnia
  phenotype_term:
    preferred_term: Sleep Disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
- name: Fatigue
  category: Systemic
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- name: Poor Appetite
  category: Systemic
  frequency: FREQUENT
  notes: Decreased or increased appetite
  phenotype_term:
    preferred_term: Poor Appetite
    term:
      id: HP:0004396
      label: Poor appetite
- name: Concentration Difficulties
  category: Cognitive
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Cognitive Impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
- name: Psychomotor Changes
  category: Neurological
  frequency: OCCASIONAL
  notes: Retardation or agitation
  phenotype_term:
    preferred_term: Psychomotor Abnormality
    term:
      id: HP:0001266
      label: Choreoathetosis
biochemical:
- name: Cortisol
  presence: Elevated
  context: HPA axis hyperactivity
  evidence:
  - reference: PMID:38331979
    reference_title: "Major depressive disorder: hypothesis, mechanism, prevention and treatment."
    supports: SUPPORT
    snippet: "The currently widely accepted theories of MDD pathogenesis include the
      neurotransmitter and receptor hypothesis, hypothalamic-pituitary-adrenal (HPA)
      axis hypothesis, cytokine hypothesis, neuroplasticity hypothesis and systemic
      influence hypothesis"
    explanation: The HPA axis hypothesis supports elevated cortisol as a key
      biochemical feature of MDD.
- name: BDNF
  presence: Decreased
  context: Reduced neuroplasticity marker
  evidence:
  - reference: PMID:38474387
    reference_title: "Role of Inflammatory Mechanisms in Major Depressive Disorder: From Etiology to Potential Pharmacological Targets."
    supports: SUPPORT
    snippet: "neuroinflammation and gut dysbiosis induce alterations in tryptophan
      metabolism, culminating in decreased serotonin synthesis, impairments in neuroplasticity-related
      mechanisms, and glutamate-mediated excitotoxicity."
    explanation: This demonstrates how neuroplasticity-related mechanisms are
      impaired in MDD, which is consistent with decreased BDNF as a
      neuroplasticity marker.
- name: Inflammatory Markers
  presence: Elevated
  context: IL-6, CRP, TNF-alpha
  evidence:
  - reference: PMID:38474387
    reference_title: "Role of Inflammatory Mechanisms in Major Depressive Disorder: From Etiology to Potential Pharmacological Targets."
    supports: SUPPORT
    snippet: "The increase of pro-inflammatory cytokines (interleukin (IL)-1β, IL-6,
      IL-18, and TNF-α) in individuals with depression may elicit neuroinflammatory
      processes and peripheral inflammation"
    explanation: This directly confirms elevated inflammatory cytokines
      including IL-6 and TNF-α in MDD patients.
genetic:
- name: SLC6A4
  association: Risk Factor
  notes: Serotonin transporter gene
- name: BDNF
  association: Risk Factor
  notes: Val66Met polymorphism
- name: FKBP5
  association: Risk Factor
  notes: HPA axis regulation
- name: HTR2A
  association: Risk Factor
  notes: Serotonin receptor gene
environmental:
- name: Childhood Trauma
  notes: Strong risk factor for adult depression
- name: Chronic Stress
  notes: Major precipitant
  evidence:
  - reference: PMID:38331979
    reference_title: "Major depressive disorder: hypothesis, mechanism, prevention and treatment."
    supports: SUPPORT
    snippet: "The currently widely accepted theories of MDD pathogenesis include the
      neurotransmitter and receptor hypothesis, hypothalamic-pituitary-adrenal (HPA)
      axis hypothesis, cytokine hypothesis, neuroplasticity hypothesis and systemic
      influence hypothesis"
    explanation: The HPA axis hypothesis directly relates to stress response
      dysregulation, supporting chronic stress as a major environmental
      precipitant of MDD.
- name: Social Isolation
  notes: Risk factor and consequence
- name: Substance Abuse
  notes: Bidirectional relationship
treatments:
- name: Selective Serotonin Reuptake Inhibitors (SSRIs)
  description: First-line pharmacotherapy (sertraline, escitalopram,
    fluoxetine).
  evidence:
  - reference: PMID:39150594
    reference_title: "Glutamatergic Modulators for Major Depression from Theory to Clinical Use."
    supports: SUPPORT
    snippet: "MDD is especially burdensome as approved monoamine antidepressant treatments
      have weeks-long delays before clinical benefit and low remission rates."
    explanation: This confirms the clinical use of monoamine antidepressants
      while acknowledging their limitations in terms of delayed benefit and
      incomplete remission.
- name: Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  description: Venlafaxine, duloxetine for depression with pain or fatigue.
- name: Cognitive Behavioral Therapy
  description: Evidence-based psychotherapy, comparable efficacy to medications.
- name: Electroconvulsive Therapy
  description: Most effective treatment for severe or treatment-resistant
    depression.
- name: Ketamine/Esketamine
  description: Rapid-acting treatment for treatment-resistant depression.
  evidence:
  - reference: PMID:39150594
    reference_title: "Glutamatergic Modulators for Major Depression from Theory to Clinical Use."
    supports: SUPPORT
    snippet: "Nasal administration of esketamine (Spravato®) was approved by the US
      Food and Drug Administration (FDA) in 2019 to treat adults with treatment-resistant
      depression and in 2020 for adults with MDD with acute suicidal ideation or behavior."
    explanation: This confirms FDA approval of esketamine for
      treatment-resistant depression and acute suicidal ideation/behavior in
      MDD.
  - reference: PMID:39150594
    reference_title: "Glutamatergic Modulators for Major Depression from Theory to Clinical Use."
    supports: SUPPORT
    snippet: "Based on this preclinical evidence implicating glutamate in depression
      and the rapid improvement of depression with ketamine treatment in a proof-of-concept
      trial, a range of N-methyl-D-aspartate (NMDA)-targeted therapies have been investigated."
    explanation: This explains the mechanistic basis for ketamine's rapid-acting
      antidepressant effects through NMDA receptor antagonism and glutamate
      modulation.
  - reference: PMID:39150594
    reference_title: "Glutamatergic Modulators for Major Depression from Theory to Clinical Use."
    supports: SUPPORT
    snippet: "Oral combination dextromethorphan-bupropion (AXS-05, Auvelity® extended-release
      tablet) was FDA approved in 2022 for the treatment of MDD in adults."
    explanation: This documents the approval of another glutamatergic modulator
      for MDD treatment, expanding treatment options beyond esketamine.
- name: Transcranial Magnetic Stimulation
  description: Non-invasive neuromodulation for treatment-resistant depression.
- name: Behavioral Activation
  description: Increasing engagement in rewarding activities.
discussions:
- discussion_id: gap_mdd_excitation_inhibition_imbalance_substrates
  prompt: >-
    Excitation-inhibition (E/I) imbalance in prefrontal-cingulate cortices is
    implicated in MDD pathophysiology, but what are the molecular substrates
    underlying E/I dysregulation in depression? Are GABAergic, glutamatergic,
    serotonergic, and opioidergic systems dysregulated primarily (upstream
    drivers) or secondarily (consequences of other pathophysiology)? How do
    these neurochemical systems interact to produce measurable E/I imbalance?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Excitation-Inhibition Imbalance
  - pathophysiology#Monoamine Deficiency
  - pathophysiology#Neuroplasticity Deficits
  rationale: >-
    Recent neuroimaging studies (Ge et al., 2026) demonstrate that MDD patients
    show significantly reduced Hurst exponent values (a biophysically confirmed
    proxy of cortical E/I balance) in parietal and prefrontal-cingulate cortices,
    with transcriptomic enrichment for neuronal structural organization and
    mitochondrial function. Neurochemical mapping links E/I dysregulation to
    GABAergic, opioidergic, serotonergic, and synaptic density distributions.
    However, critical gaps remain: (1) the causal direction of E/I imbalance
    relative to monoamine deficiency and HPA-axis dysregulation; (2) whether
    specific GABA receptor subtypes (α1-α6, β1-β3, γ1-γ3) or glutamate receptor
    classes (NMDA, AMPA, kainate) are preferentially dysregulated in depression;
    (3) the role of parvalbumin-positive fast-spiking interneurons and other
    inhibitory circuits in producing cortical E/I imbalance; and (4) how ketamine's
    rapid antidepressant effects via NMDA-receptor antagonism mechanistically
    relate to E/I normalization in treatment-resistant depression. Understanding
    these substrates could identify new therapeutic targets distinct from
    monoamine reuptake inhibition.
  evidence:
  - reference: PMID:42372880
    reference_title: "Intrinsic excitation-inhibition imbalance in major depressive disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Transcriptomic analysis identified enrichment for neuronal structural organization, nucleic acid metabolism, and mitochondrial function, with preferential overlap with excitatory and inhibitory neuron-specific gene sets."
    explanation: >-
      Multimodal evidence links E/I dysregulation to transcriptomic changes in
      neuronal structure and energy metabolism, supporting the mechanistic
      relevance of this imbalance in MDD.
  - reference: PMID:42372880
    reference_title: "Intrinsic excitation-inhibition imbalance in major depressive disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Divergent group-by-treatment effects were observed in the anterior cingulate and medial prefrontal cortices, with ketamine-induced increases in TRD patients."
    explanation: >-
      The differential effect of ketamine on cortical E/I balance in
      treatment-resistant depression suggests E/I normalization as a putative
      mechanism underlying rapid antidepressant action, but the molecular
      pathway from NMDA antagonism to E/I balance restoration remains unresolved.
  proposed_experiments:
  - experiment_id: exp_mdd_ei_substrate_specificity
    name: Map GABA and glutamate receptor subtype dysregulation across cortical regions in MDD
    description: >-
      Using postmortem brain tissue from MDD and control subjects, perform
      multi-region quantification of GABA receptor subtype expression (α1-α6,
      β1-β3, γ1-γ3) and glutamate receptor class expression (GluN1/GluN2, GluA1-A4,
      GluK1-K5) via Western blot, qPCR, and in situ hybridization in
      prefrontal-cingulate cortices. Correlate subtype-specific changes with
      lifetime depression severity and antidepressant medication history.
    experiment_type:
      preferred_term: postmortem brain tissue analysis
  - experiment_id: exp_mdd_ei_interneuron_circuits
    name: Determine whether parvalbumin-positive interneuron dysfunction drives cortical E/I imbalance in depression models
    description: >-
      In chronic-stress depression models and acute-stress models, use
      electrophysiology and optogenetics to measure inhibitory tone from
      parvalbumin-positive fast-spiking interneurons onto pyramidal neurons.
      Assess whether targeted optogenetic reactivation of inhibitory circuits
      restores cortical E/I balance and reverses depression-like behavior.
      Parallel human studies using MEG/EEG to measure cortical oscillatory power
      and phase-amplitude coupling as surrogates of interneuron function.
    experiment_type:
      preferred_term: in vivo electrophysiology and optogenetics
  - experiment_id: exp_mdd_ketamine_ei_restoration
    name: Test whether ketamine's rapid antidepressant effect requires cortical E/I rebalancing
    description: >-
      In acute-stress depression models, measure time-resolved Hurst exponent and
      cortical E/I balance before, during (minutes to hours), and after ketamine
      administration. Assess whether E/I normalization precedes or follows
      behavioral antidepressant effects. Simultaneously measure monoamine levels
      and HPA-axis markers to determine temporal ordering and mechanistic
      independence of E/I rebalancing from classical monoamine pathways.
    experiment_type:
      preferred_term: in vivo neuroimaging and electrophysiology during pharmacological intervention
- discussion_id: gap_mdd_oligodendrocyte_dysfunction
  prompt: >-
    Emerging evidence implicates oligodendrocyte (OL) dysfunction and myelin
    abnormalities in major depressive disorder, extending beyond classical
    myelination to neural plasticity, neuronal metabolic support, and circuit
    regulation. Is OL/white-matter pathology a primary driver of MDD, or a
    secondary consequence of neuroinflammation, chronic stress, and HPA-axis
    hyperactivity? Which OL subsets and brain regions are most mechanistically
    relevant, and how does OL-astrocyte-microglia crosstalk causally link to
    depressive symptoms?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Oligodendrocyte Dysfunction and Demyelination
  - pathophysiology#Neuroplasticity Deficits
  - pathophysiology#Neuroinflammation
  - pathophysiology#HPA Axis Dysregulation
  rationale: >-
    Neuroimaging consistently shows white-matter and brain-connectivity
    alterations in MDD, and post-mortem and animal studies report reduced
    oligodendrocyte density, downregulated myelin-related genes, and myelin
    abnormalities. The Gan et al. (2026) review argues that OL dysfunction is a
    key pathophysiological mechanism in MDD that extends beyond myelination to
    include contributions to neural plasticity, metabolic support, and circuit
    regulation, manifesting primarily as myelin abnormalities tied to altered
    connectivity and emotional processing. What remains unresolved is the causal
    direction: whether OL/myelin pathology initiates circuit dysfunction and
    depressive symptoms, or whether it is downstream of neuroinflammation,
    glucocorticoid excess from HPA-axis hyperactivity, and impaired
    neuroplasticity. The relative importance of distinct OL populations
    (mature OLs vs. oligodendrocyte precursor cells) and region-specific
    contributions (prefrontal cortex vs. hippocampus) is also unknown. Because
    OLs interact bidirectionally with neurons, astrocytes, and microglia,
    disentangling OL-glial crosstalk from primary inflammatory signaling is
    difficult with cross-sectional human data. Resolving these questions would
    clarify whether remyelination-promoting or OL-protective strategies could
    serve as disease-modifying treatments rather than symptomatic ones.
  proposed_experiments:
  - experiment_id: exp_mdd_ol_causality_remyelination
    name: Region-specific oligodendrocyte manipulation with longitudinal connectivity and behavioral readouts
    description: >-
      In a chronic-stress rodent model of depression, use cell-type-specific
      genetic and pharmacological tools to (a) deplete or impair mature
      oligodendrocytes and oligodendrocyte precursor cells in prefrontal cortex
      versus hippocampus, and (b) conversely promote remyelination, while
      measuring myelin integrity, neuroinflammatory glial activation, neural
      circuit connectivity, and depression-like behavior. Pair with a human
      cohort combining diffusion-MRI white-matter metrics, peripheral
      inflammatory markers, and longitudinal symptom trajectories to test
      temporal ordering of white-matter change relative to inflammation and
      symptom onset.
    experiment_type:
      preferred_term: cell-type-specific perturbation with longitudinal imaging and behavioral phenotyping
    readouts:
    - name: Myelin integrity and white-matter connectivity
      target: pathophysiology#Neuroplasticity Deficits
      description: >
        Quantify myelin sheath thickness, oligodendrocyte density, and
        white-matter tract connectivity (diffusion imaging) to test whether
        manipulating OL/myelin alters circuit structure independent of
        inflammation.
      assays:
      - preferred_term: diffusion tensor imaging
      - preferred_term: myelin histopathology
      direction: NEGATIVE
    - name: Glial neuroinflammatory activation
      target: pathophysiology#Neuroinflammation
      description: >
        Measure microglial and astrocyte activation and proinflammatory
        cytokine levels to determine whether OL dysfunction precedes or follows
        neuroinflammatory signaling.
      assays:
      - preferred_term: glial activation immunostaining
      - preferred_term: cytokine quantification
      direction: POSITIVE
    - name: Depression-like behavior and symptom trajectory
      target: pathophysiology#HPA Axis Dysregulation
      description: >
        Assess depression-like behavior in animals and longitudinal depressive
        symptom severity in humans relative to stress/glucocorticoid exposure to
        test whether OL-targeted intervention modifies outcome.
      assays:
      - preferred_term: depression behavioral battery
      direction: NEGATIVE
    decision_criterion: >-
      OL dysfunction is supported as a primary driver if region-specific OL
      depletion produces white-matter and depression-like phenotypes before or
      independent of neuroinflammatory activation, and if remyelination-promoting
      intervention reverses depressive behavior; it is supported as a secondary
      consequence if white-matter change consistently follows inflammatory and
      glucocorticoid signaling and OL manipulation alone does not alter
      depressive outcomes.
    would_support:
    - pathophysiology#Neuroplasticity Deficits
    - pathophysiology#Neuroinflammation
  evidence:
  - reference: PMID:41730818
    reference_title: "Oligodendrocyte dysfunction in major depressive disorder: Mechanistic insights and emerging therapies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Emerging evidence increasingly implicates oligodendrocyte (OL) dysfunction as a key pathophysiological mechanism in MDD, extending beyond their classical role in myelination to include critical contributions to neural plasticity, metabolic support, and circuit regulation."
    explanation: >-
      This review establishes OL dysfunction as an emerging mechanistic
      hypothesis in MDD that extends beyond myelination, motivating the
      knowledge gap about its role and causal position.
  - reference: PMID:41730818
    reference_title: "Oligodendrocyte dysfunction in major depressive disorder: Mechanistic insights and emerging therapies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Finally, we highlight key knowledge gaps and propose future research directions aimed at clarifying the contribution of OL biology to depressive disorders and improving treatment outcomes."
    explanation: >-
      The authors explicitly flag unresolved knowledge gaps and call for
      research clarifying the contribution of OL biology to depression,
      directly supporting this KNOWLEDGE_GAP entry.
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
datasets:
references:
- reference: DOI:10.1007/s40263-024-01114-y
  title: Glutamatergic Modulators for Major Depression from Theory to Clinical
    Use
  findings: []
- reference: DOI:10.1038/s41392-024-01738-y
  title: 'Major depressive disorder: hypothesis, mechanism, prevention and treatment'
  findings: []
- reference: DOI:10.1101/2025.05.03.25326369
  title: 'Multi-omics insights in major depressive disorder: Dysfunction of Neurons'
  findings: []
- reference: DOI:10.3390/cells13050423
  title: 'Role of Inflammatory Mechanisms in Major Depressive Disorder: From Etiology
    to Potential Pharmacological Targets'
  findings: []
- reference: DOI:10.3390/ijms25020963
  title: 'Mitochondrial and Cellular Function in Fibroblasts, Induced Neurons, and
    Astrocytes Derived from Case Study Patients: Insights into Major Depression as
    a Mitochondria-Associated Disease'
  findings: []
- reference: DOI:10.3390/ijtm4010010
  title: 'Advancements Exploring Major Depressive Disorder: Insights on Oxidative
    Stress, Serotonin Metabolism, BDNF, HPA Axis Dysfunction, and Pharmacotherapy
    Advances'
  findings: []

📚

References & Deep Research

References

6

DOI:10.1007/s40263-024-01114-y

Glutamatergic Modulators for Major Depression from Theory to Clinical Use

No top-level findings curated for this source.

DOI:10.1038/s41392-024-01738-y

Major depressive disorder: hypothesis, mechanism, prevention and treatment

No top-level findings curated for this source.

DOI:10.1101/2025.05.03.25326369

Multi-omics insights in major depressive disorder: Dysfunction of Neurons

No top-level findings curated for this source.

DOI:10.3390/cells13050423

Role of Inflammatory Mechanisms in Major Depressive Disorder: From Etiology to Potential Pharmacological Targets

No top-level findings curated for this source.

DOI:10.3390/ijms25020963

Mitochondrial and Cellular Function in Fibroblasts, Induced Neurons, and Astrocytes Derived from Case Study Patients: Insights into Major Depression as a Mitochondria-Associated Disease

No top-level findings curated for this source.

DOI:10.3390/ijtm4010010

Advancements Exploring Major Depressive Disorder: Insights on Oxidative Stress, Serotonin Metabolism, BDNF, HPA Axis Dysfunction, and Pharmacotherapy Advances

No top-level findings curated for this source.

Deep Research

2

Disorder ▸

Disorder

Name: Major Depressive Disorder
Category: Complex
Existing deep-research providers: falcon
Existing evidence reference count in YAML: 28

Key Pathophysiology Nodes

Monoamine Deficiency
HPA Axis Dysregulation
Neuroplasticity Deficits
Neuroinflammation
Mitochondrial Dysfunction
Deep research literature mapping

Citation Inventory (for evidence mapping)

DOI:10.1007/s40263-024-01114-y
DOI:10.1038/s41392-024-01738-y
DOI:10.1101/2025.05.03.25326369
DOI:10.3390/cells13050423
DOI:10.3390/ijms25020963
DOI:10.3390/ijtm4010010

Falcon ▸

Disease Pathophysiology Research Report

Edison Scientific Literature 19 citations 2025-12-17T18:55:49.493721

Disease Pathophysiology Research Report

Target Disease - Disease Name: Major Depressive Disorder - MONDO ID: MONDO:0009409 - Category: Complex

Pathophysiology description MDD is a heterogeneous, systems‑level brain disorder arising from convergent dysregulation of neurotransmission, stress–neuroendocrine control, immune–metabolic signaling, cellular bioenergetics, and neuroplasticity within limbic–prefrontal circuits. Contemporary models integrate: (a) monoaminergic signaling deficits (serotonin, noradrenaline, dopamine); (b) glutamate/GABA excitation–inhibition imbalance with synaptic and postsynaptic plasticity failure; (c) HPA axis hyperactivity with glucocorticoid receptor resistance; (d) innate/adaptive immune activation that biases tryptophan metabolism along the kynurenine pathway toward neurotoxic metabolites; (e) mitochondrial respiratory dysfunction, oxidative stress, and altered calcium/ATP homeostasis in neurons and glia; (f) oligodendrocyte lineage/myelination abnormalities that compromise long‑range circuit conduction; and (g) network‑scale synaptic vesicle and postsynaptic density perturbations in subgenual/anterior cingulate, prefrontal cortex, hippocampus, and amygdala (Cui 2024; McIntyre & Jain 2024; Kouba 2024; Correia & Vale 2024; Wetzel 2024; Zhang et al. 2025 preprint) (cui2024majordepressivedisorder pages 23-24, mcintyre2024glutamatergicmodulatorsfor pages 7-9, kouba2024roleofinflammatory pages 2-3, correia2024advancementsexploringmajor pages 1-2, wetzel2024mitochondrialandcellular pages 10-12, zhang2025multiomicsinsightsin pages 14-18).

Core Pathophysiology 1) Monoamine hypothesis, refined: Serotonin, noradrenaline, and dopamine pathway alterations interact with stress biology and neurotrophic signaling. Despite efficacy of monoamine reuptake inhibitors, non‑remission remains high (~30%), indicating additional pathobiology beyond monoamines (Cui 2024; Correia & Vale 2024) (cui2024majordepressivedisorder pages 23-24, correia2024advancementsexploringmajor pages 1-2). URL examples: https://doi.org/10.1038/s41392-024-01738-y (2024); https://doi.org/10.3390/ijtm4010010 (2024). 2) Glutamate/GABA and synaptic plasticity failure: Human and preclinical evidence implicates reduced GABAergic tone, altered NMDA/AMPA signaling, and impaired synaptogenesis; rapid‑acting agents (ketamine/esketamine, dextromethorphan–bupropion) exploit this pathway (McIntyre & Jain 2024) (mcintyre2024glutamatergicmodulatorsfor pages 7-9). URL: https://doi.org/10.1007/s40263-024-01114-y (2024). 3) Neurotrophic/BDNF signaling: Reduced BDNF and altered TrkB signaling are linked with hippocampal atrophy and impaired synaptogenesis; stress and oxidative–HPA dysregulation suppress BDNF expression and signaling (Correia & Vale 2024; Cui 2024) (correia2024advancementsexploringmajor pages 1-2, cui2024majordepressivedisorder pages 23-24). URL: https://doi.org/10.3390/ijtm4010010 (2024); https://doi.org/10.1038/s41392-024-01738-y (2024). 4) HPA axis dysregulation: Chronic stress elevates cortisol, disrupts glucocorticoid receptor (GR) feedback, and damages hippocampal circuits. Reviews highlight patient subsets with marked HPA abnormality and propose precision testing (e.g., dex‑CRH) to match HPA‑targeted therapies (Cui 2024) (cui2024majordepressivedisorder pages 23-24). URL: https://doi.org/10.1038/s41392-024-01738-y (2024). 5) Immune–inflammation and kynurenine pathway: Elevated cytokines (IL‑6, IL‑1β, TNF‑α) and microglial–astrocytic interactions shift tryptophan metabolism via IDO1/KMO toward 3‑hydroxykynurenine and quinolinic acid (NMDA agonist), reducing serotonin bioavailability and promoting excitotoxic stress (Kouba 2024) (kouba2024roleofinflammatory pages 2-3). URL: https://doi.org/10.3390/cells13050423 (2024). 6) Mitochondrial bioenergetics and oxidative stress: Patient‑derived astrocytes and neurons show reduced basal/maximal respiration, altered mitochondrial membrane potential and calcium handling, and ATP shortfalls, consistent with oxidative–bioenergetic deficits contributing to impaired neuroplasticity (Wetzel 2024) (wetzel2024mitochondrialandcellular pages 10-12). URL: https://doi.org/10.3390/ijms25020963 (2024). 7) Myelination/oligodendrocytes: Single‑cell and multi‑omics analyses associate MDD with oligodendrocyte lineage and excitatory neuron dysfunction in prefrontal cortex, implicating myelin and axonal support in mood‑circuit dysconnectivity (Cui 2024; Zhang et al. 2025 preprint) (cui2024majordepressivedisorder pages 23-24, zhang2025multiomicsinsightsin pages 14-18). URL: https://doi.org/10.1038/s41392-024-01738-y (2024); https://doi.org/10.1101/2025.05.03.25326369 (2025 preprint). 8) Synaptic function: Transcriptomic signatures converge on synaptic vesicle cycling, postsynaptic density, and splicing programs in excitatory neurons (Zhang et al. 2025 preprint; Cui 2024) (zhang2025multiomicsinsightsin pages 14-18, cui2024majordepressivedisorder pages 23-24). URL: https://doi.org/10.1101/2025.05.03.25326369 (2025 preprint); https://doi.org/10.1038/s41392-024-01738-y (2024).

Key Molecular Players - Genes/Proteins (HGNC): BDNF; NTRK2; CREB1; GRIN1/GRIN2A (NMDA receptor subunits); GRIA1 (AMPA); GAD1; GABRA1/GABRD (GABAA subunits); SLC6A4 (SERT); IDO1; KMO; IL6; IL1B; TNF; NR3C1 (GR); FKBP5; mitochondrial bioenergetics genes (e.g., SLC25A5/ANT2, ALDH2, IMMT) (Correia 2024; Kouba 2024; Wetzel 2024; Cui 2024; McIntyre & Jain 2024) (correia2024advancementsexploringmajor pages 1-2, kouba2024roleofinflammatory pages 2-3, wetzel2024mitochondrialandcellular pages 10-12, cui2024majordepressivedisorder pages 23-24, mcintyre2024glutamatergicmodulatorsfor pages 7-9). URLs: https://doi.org/10.3390/ijtm4010010 (2024); https://doi.org/10.3390/cells13050423 (2024); https://doi.org/10.3390/ijms25020963 (2024); https://doi.org/10.1038/s41392-024-01738-y (2024); https://doi.org/10.1007/s40263-024-01114-y (2024). - Chemical Entities (CHEBI): Ketamine/esketamine; dextromethorphan; bupropion; allopregnanolone analogs (brexanolone, zuranolone); monoamine reuptake inhibitors; kynurenine pathway metabolites (kynurenine, quinolinic acid) (McIntyre & Jain 2024; Kouba 2024; Cui 2024) (mcintyre2024glutamatergicmodulatorsfor pages 7-9, kouba2024roleofinflammatory pages 2-3, cui2024majordepressivedisorder pages 23-24). - Cell Types (CL): Cortical excitatory neurons; GABAergic interneurons (SST+, PVALB+); astrocytes; microglia; oligodendrocyte precursor cells and mature oligodendrocytes (Cui 2024; Kouba 2024; Wetzel 2024; Zhang et al. 2025 preprint) (cui2024majordepressivedisorder pages 23-24, kouba2024roleofinflammatory pages 2-3, wetzel2024mitochondrialandcellular pages 10-12, zhang2025multiomicsinsightsin pages 14-18). - Anatomical Locations (UBERON): Subgenual anterior cingulate cortex, dorsolateral prefrontal cortex, hippocampus, amygdala, hypothalamus–pituitary–adrenal axis structures (Cui 2024; Zhang et al. 2025 preprint) (cui2024majordepressivedisorder pages 23-24, zhang2025multiomicsinsightsin pages 14-18).

Biological Processes (GO annotations) - Synaptic transmission and plasticity: GO:0007268 (neurotransmitter receptor signaling), GO:0048167 (regulation of synaptic plasticity) (Correia 2024; McIntyre & Jain 2024) (correia2024advancementsexploringmajor pages 1-2, mcintyre2024glutamatergicmodulatorsfor pages 7-9). - Stress and HPA signaling: GO:0006950 (response to stress), GO terms related to glucocorticoid receptor signaling (Cui 2024) (cui2024majordepressivedisorder pages 23-24). - Inflammation and kynurenine metabolism: GO:0006954 (inflammatory response), GO terms for kynurenine metabolic process (Kouba 2024) (kouba2024roleofinflammatory pages 2-3). - Mitochondrial respiration/oxidative stress: GO:0006119 (oxidative phosphorylation/respiration), GO:0006979 (response to oxidative stress) (Wetzel 2024) (wetzel2024mitochondrialandcellular pages 10-12). - Myelination/oligodendrocyte differentiation: GO:0042552 (myelination), GO:0014003 (oligodendrocyte development) (Cui 2024; Zhang 2025 preprint) (cui2024majordepressivedisorder pages 23-24, zhang2025multiomicsinsightsin pages 14-18).

Cellular Components (GO CC) - Postsynaptic density; synaptic vesicle; mitochondrial inner membrane; myelin sheath; extrasynaptic GABAA receptor complexes (Cui 2024; McIntyre & Jain 2024; Wetzel 2024) (cui2024majordepressivedisorder pages 23-24, mcintyre2024glutamatergicmodulatorsfor pages 7-9, wetzel2024mitochondrialandcellular pages 10-12).

Disease Progression (sequence of events) - Stress/early adversity and genetic susceptibility activate HPA axis and peripheral immune signals → elevated cortisol and cytokines drive GR resistance, microglial activation, and IDO1/KMO upregulation → tryptophan diverted from serotonin to neurotoxic kynurenines (quinolinic acid), promoting NMDA‑mediated excitotoxicity → mitochondrial dysfunction and oxidative stress further impair synaptic plasticity and neurogenesis → network‑level deficits in glutamate/GABA balance, synaptic vesicle trafficking, and myelination in prefrontal–limbic circuits → clinical manifestations (anhedonia, low mood, cognitive dysfunction) and variable treatment response (Cui 2024; Kouba 2024; Correia & Vale 2024; Wetzel 2024) (cui2024majordepressivedisorder pages 23-24, kouba2024roleofinflammatory pages 2-3, correia2024advancementsexploringmajor pages 1-2, wetzel2024mitochondrialandcellular pages 10-12). URLs: https://doi.org/10.1038/s41392-024-01738-y (2024); https://doi.org/10.3390/cells13050423 (2024); https://doi.org/10.3390/ijtm4010010 (2024); https://doi.org/10.3390/ijms25020963 (2024).

Phenotypic Manifestations (HP terms) - Depressed mood (HP:0000716), anhedonia (HP:0034259), psychomotor changes (HP:0000752), sleep disturbance (HP:0002360), cognitive impairment (HP:0100543). Mechanistic mapping: reduced BDNF/neuroplasticity and mitochondrial ATP constrain cognitive circuits; E/I imbalance (glutamate/GABA) contributes to anhedonia and mood reactivity; HPA/immune–kynurenine perturbations align with sleep and energy dysregulation (Cui 2024; Correia & Vale 2024; Kouba 2024) (cui2024majordepressivedisorder pages 23-24, correia2024advancementsexploringmajor pages 1-2, kouba2024roleofinflammatory pages 2-3).

Current applications and real‑world implementations - Ketamine and intranasal esketamine: Rapid symptom reduction in TRD, mechanistically linked to NMDA antagonism → AMPA throughput → BDNF/mTOR synaptogenesis; considerations include dissociation, cardiovascular/urinary effects, scheduling, and supervised administration. Regulatory approvals (e.g., 2019 for esketamine) and clinical adoption are summarized (McIntyre & Jain 2024; review) (mcintyre2024glutamatergicmodulatorsfor pages 7-9). URL: https://doi.org/10.1007/s40263-024-01114-y (2024). - Dextromethorphan–bupropion (AXS‑05/Auvelity): Oral agent combining NMDA antagonism and sigma‑1 agonism with monoaminergic effects; approved for MDD and positioned as a glutamatergic modulator with favorable practicality relative to parenteral ketamine (McIntyre & Jain 2024) (mcintyre2024glutamatergicmodulatorsfor pages 7-9). URL: https://doi.org/10.1007/s40263-024-01114-y (2024). - Neurosteroids (brexanolone IV; zuranolone oral): Positive allosteric modulators of GABAA receptors (including extrasynaptic δ‑subunit‑containing receptors) providing rapid relief in postpartum depression and informing GABAergic deficits in depressive pathophysiology (Correia & Vale 2024; Cui 2024) (correia2024advancementsexploringmajor pages 1-2, cui2024majordepressivedisorder pages 23-24). URLs: https://doi.org/10.3390/ijtm4010010 (2024); https://doi.org/10.1038/s41392-024-01738-y (2024).

Expert opinions and analysis from authoritative sources - Signal Transduction and Targeted Therapy (Cui 2024) synthesizes MDD as multisystem with neuroplasticity, HPA, immune and metabolic/mitochondrial axes, advocating for multi‑organ, multi‑target treatments and improved animal models (cui2024majordepressivedisorder pages 23-24). URL: https://doi.org/10.1038/s41392-024-01738-y (2024). - CNS Drugs review (McIntyre & Jain 2024) details the translational arc of glutamatergic agents, highlighting successes (esketamine, AXS‑05) and failures of several NMDA‑site modulators, underscoring synaptic plasticity’s centrality and the need for safety/access frameworks (mcintyre2024glutamatergicmodulatorsfor pages 7-9). URL: https://doi.org/10.1007/s40263-024-01114-y (2024). - Cells review (Kouba 2024) integrates immune–kynurenine mechanisms with glutamate toxicity and neuroplasticity failure, supporting immunopsychiatry approaches (kouba2024roleofinflammatory pages 2-3). URL: https://doi.org/10.3390/cells13050423 (2024). - IJMS case‑based translational work (Wetzel 2024) provides cellular bioenergetics evidence for mitochondrial involvement in MDD glia and neurons, aligning with precision‐medicine biomarker development (wetzel2024mitochondrialandcellular pages 10-12). URL: https://doi.org/10.3390/ijms25020963 (2024).

Relevant statistics and data from recent studies - Non‑remission remains substantial with current monoaminergic approaches (~30%), motivating mechanistically targeted therapies (Cui 2024) (cui2024majordepressivedisorder pages 23-24). - Translational approvals: esketamine (2019) for TRD; dextromethorphan–bupropion (2022) for MDD—illustrating the clinical impact of glutamatergic modulation (McIntyre & Jain 2024) (mcintyre2024glutamatergicmodulatorsfor pages 7-9). - Cellular bioenergetics (patient‑derived astrocytes): reduced basal and maximal respiration and ATP‑related oxygen consumption; altered mitochondrial membrane potential and calcium handling, supporting bioenergetic load in symptom biology (Wetzel 2024) (wetzel2024mitochondrialandcellular pages 10-12).

Ontology‑aligned annotations - Genes/Proteins (HGNC): BDNF; NTRK2; GRIN1/2A; GRIA1; GAD1; GABRA1/GABRD; SLC6A4; IDO1; KMO; IL6; IL1B; TNF; NR3C1; FKBP5; SLC25A5; ALDH2; IMMT (correia2024advancementsexploringmajor pages 1-2, kouba2024roleofinflammatory pages 2-3, wetzel2024mitochondrialandcellular pages 10-12, cui2024majordepressivedisorder pages 23-24, mcintyre2024glutamatergicmodulatorsfor pages 7-9). - GO Biological Processes: neurotransmitter receptor signaling (GO:0007268); regulation of synaptic plasticity (GO:0048167/GO:0048168); inflammatory response (GO:0006954); response to stress (GO:0006950); mitochondrial respiration (GO:0006119); myelination (GO:0042552) (mcintyre2024glutamatergicmodulatorsfor pages 7-9, kouba2024roleofinflammatory pages 2-3, wetzel2024mitochondrialandcellular pages 10-12, cui2024majordepressivedisorder pages 23-24). - Cell Types (CL): cortical excitatory neuron; GABAergic interneuron (SST+, PVALB+); astrocyte; microglial cell; oligodendrocyte precursor cell; oligodendrocyte (cui2024majordepressivedisorder pages 23-24, kouba2024roleofinflammatory pages 2-3, wetzel2024mitochondrialandcellular pages 10-12, zhang2025multiomicsinsightsin pages 14-18). - Anatomical locations (UBERON): subgenual anterior cingulate cortex; dorsolateral prefrontal cortex; hippocampus; amygdala; hypothalamus–pituitary–adrenal axis (cui2024majordepressivedisorder pages 23-24, zhang2025multiomicsinsightsin pages 14-18). - Cellular Components (GO CC): postsynaptic density; synaptic vesicle; mitochondrial inner membrane; myelin sheath; extrasynaptic GABAA receptor complex (mcintyre2024glutamatergicmodulatorsfor pages 7-9, wetzel2024mitochondrialandcellular pages 10-12, cui2024majordepressivedisorder pages 23-24). - Chemicals (CHEBI): ketamine; esketamine; dextromethorphan; bupropion; allopregnanolone analogs (brexanolone, zuranolone); kynurenine; quinolinic acid (mcintyre2024glutamatergicmodulatorsfor pages 7-9, kouba2024roleofinflammatory pages 2-3, cui2024majordepressivedisorder pages 23-24). - Phenotypes (HP): depressed mood (HP:0000716); anhedonia (HP:0034259); psychomotor changes (HP:0000752); sleep disturbance (HP:0002360); cognitive impairment (HP:0100543) (cui2024majordepressivedisorder pages 23-24, correia2024advancementsexploringmajor pages 1-2).

Embedded Evidence Map | Domain / Pathway | Key mechanisms (1–2 sentences) | Representative genes / proteins (HGNC) | Cell types (CL) | Anatomical loci (UBERON) | GO biological processes (GO BP) | Key chemicals / drugs (CHEBI) | Recent evidence (DOI / URL / Year; brief quantitative data) | |---|---|---:|---|---|---|---|---| | Monoamine (serotonin/dopamine/noradrenaline) | Reduced monoaminergic signaling and altered transporter/receptor function impair mood regulation and reward; interacts with HPA and immune axes. | SLC6A4, TPH2, MAOA, DRD2 | Serotonergic & dopaminergic neurons; astrocytes | Raphe nuclei; ventral tegmental area; prefrontal cortex, striatum | "monoamine transport"; "neurotransmitter receptor signaling" (GO:0007268) | SSRIs (e.g., escitalopram), SNRIs (venlafaxine) | Comprehensive 2024 review summarizing monoamine + multisystem interplay: Cui et al., doi:10.1038/s41392-024-01738-y (2024) ("~30% non-remission" noted) (cui2024majordepressivedisorder pages 23-24) | | Glutamate–GABA (excitation–inhibition) | Dysregulated glutamatergic excitation and GABAergic inhibition (reduced GABA, altered NMDA/AMPA signaling) → impaired E/I balance, excitotoxic risk and rapid-acting glutamatergic therapeutics. | GRIN1/GRIN2A, GRIA1, GABRA1, GAD1 | Excitatory (glutamatergic) neurons; inhibitory interneurons (SST, PVALB); astrocytes | Prefrontal cortex (dlPFC), anterior cingulate, hippocampus | "synaptic transmission"; "regulation of membrane potential" (GO:0007269) | Ketamine, esketamine, dextromethorphan; memantine | Glutamate-targeted translational successes and trial landscape; approvals: esketamine (2019), AXS‑05 (dextromethorphan–bupropion) discussed (McIntyre & Jain, doi:10.1007/s40263-024-01114-y, 2024) (mcintyre2024glutamatergicmodulatorsfor pages 7-9) | | Neuroplasticity / BDNF | Reduced BDNF expression and impaired TrkB signaling → decreased synaptogenesis, neurogenesis and structural atrophy (hippocampus) linking stress to circuit dysfunction. | BDNF, NTRK2 (TrkB), CREB1 | Neurons (excitatory), astrocytes | Hippocampus, prefrontal cortex | "synaptic plasticity" (GO:0048167); "neurotrophin signaling" | Exercise, traditional antidepressants; ketamine (indirectly increases BDNF) | BDNF–MDD mechanistic review summarizing exon/epigenetic links and clinical correlations: Correia & Vale, doi:10.3390/ijtm4010010 (2024) (correia2024advancementsexploringmajor pages 8-9, correia2024advancementsexploringmajor pages 1-2) | | HPA axis – cortisol / stress | Chronic HPA hyperactivity, glucocorticoid receptor (GR/NR3C1) resistance and elevated cortisol cause hippocampal vulnerability, reduced neurogenesis, and immune modulation. | CRH, NR3C1, FKBP5 | Hypothalamic neuroendocrine cells; hippocampal neurons; immune cells | Hypothalamus; pituitary; hippocampus | "response to stress" (GO:0006950); "glucocorticoid receptor signaling" | GR modulators (experimental) | HPA axis as precision target; reviews highlight subset HPA abnormalities and need for companion diagnostics (dex‑CRH/mDST): Menke et al. (cui2024majordepressivedisorder pages 23-24) and HPA-focused reviews (cui2024majordepressivedisorder pages 23-24, correia2024advancementsexploringmajor pages 1-2) (2024) | | Immune — inflammation & kynurenine | Peripheral/central inflammation (IL‑6, IL‑1β, TNF‑α) activates microglia, shifts tryptophan metabolism via IDO1/KMO toward neurotoxic kynurenines (3‑HK, quinolinic acid) reducing serotonin and promoting excitotoxicity. | IL6, IL1B, TNF, IDO1, KMO, KYNU | Microglia, astrocytes, peripheral monocytes | Blood–brain interface; hippocampus; PFC | "inflammatory response" (GO:0006954); "kynurenine metabolic process" | Anti‑inflammatories (investigational), kynurenine pathway modulators (experimental) | Inflammation–kynurenine mechanistic review and therapeutic implications: Kouba et al., doi:10.3390/cells13050423 (2024) (kouba2024roleofinflammatory pages 2-3) | | Mitochondria / oxidative stress & bioenergetics | Impaired mitochondrial respiration, altered membrane potential, disrupted Ca2+ homeostasis and increased ROS → reduced ATP, neuroplasticity deficits and vulnerability to stress. | SLC25A5, ALDH2, IMMT (examples); PGC1A (PPARGC1A) | Neurons, astrocytes, oligodendrocytes, peripheral immune cells | Prefrontal cortex; hippocampus; systemic (blood biomarkers) | "mitochondrial respiration" (GO:0006119); "response to oxidative stress" (GO:0006979) | CoQ10, antioxidants (nutraceuticals; investigational) | Patient‑derived cell evidence: decreased basal/maximal respiration, lower mitochondrial membrane potential in MDD astrocytes and case studies (Wetzel et al., doi:10.3390/ijms25020963, 2024) (wetzel2024mitochondrialandcellular pages 10-12) | | Circadian / sleep | Circadian clock gene dysregulation and sleep disturbance disrupts hormonal, immune and metabolic rhythms, exacerbating vulnerability to depression and impairing recovery. | CLOCK, BMAL1 (ARNTL), PER1, CRY1 | Suprachiasmatic nucleus neurons; cortical neurons; peripheral cells | Suprachiasmatic nucleus; prefrontal cortex; systemic | "circadian regulation of gene expression" (GO:0032922); "sleep regulation" | Melatonin, chronotherapies (light/behavioral) | Circadian–sleep review linking clock gene expression to depressive symptom severity and therapeutic opportunities: Gabryelska et al., doi:10.1038/s41398-024-03134-0 (2024) (mcintyre2024glutamatergicmodulatorsfor pages 7-9) | | Myelination / oligodendrocytes | Oligodendrocyte lineage dysfunction and altered myelination impair circuit conduction and metabolic support for neurons, contributing to mood circuit dysconnectivity. | MBP, OLIG2, PDGFRA, MOG | Oligodendrocyte precursor cells (OPCs), mature oligodendrocytes | Prefrontal cortex (white matter tracts), hippocampus | "myelination" (GO:0042552); "oligodendrocyte differentiation" | Remyelination strategies (emerging); indirect effect of antidepressants | Emerging evidence implicates OPCs / oligodendrocyte changes in MDD from single‑cell and translational studies (single‑cell findings summarized in Zhang preprint and reviews in 2024–25) (zhang2025multiomicsinsightsin pages 14-18, cui2024majordepressivedisorder pages 23-24) | | Synaptic function & vesicular trafficking | Altered synaptic vesicle cycling, postsynaptic density proteins and splicing lead to deficient neurotransmission and network-level dysregulation in mood circuits. | SYN1, PSD95 (DLG4), SYNAPTOTAGMINS, RAB proteins | Excitatory & inhibitory neurons; presynaptic terminals; astrocytes | Subgenual ACC, amygdala, dlPFC | "synaptic vesicle cycle" (GO:0099504); "postsynaptic density organization" | Synaptogenic agents (ketamine‑linked plasticity) | Large‑scale transcriptomic/single‑cell analyses reveal convergent dysregulation of synaptic and vesicular pathways in excitatory neurons (dlPFC/subgenual ACC): Goes et al., integrative findings summarized in multi‑omics preprints/reviews (zhang2025multiomicsinsightsin pages 14-18, cui2024majordepressivedisorder pages 23-24) (2024–2025) | | Translational — Ketamine / Esketamine | NMDA receptor antagonism → transient disinhibition of glutamate release, AMPA activation, BDNF/mTOR signaling and rapid synaptogenesis; rapid antidepressant but safety/abuse considerations limit use. | GRINs, BDNF, mTOR (FRAP1) | Cortical excitatory neurons; interneurons; microglia (immune effects) | Prefrontal cortex; limbic circuits | "regulation of synaptic plasticity" (GO:0048168) | Ketamine (R,S), Esketamine (S) | Clinical trial landscape and approvals; esketamine approved 2019; overview and trial trends (McIntyre & Jain, doi:10.1007/s40263-024-01114-y, 2024) (mcintyre2024glutamatergicmodulatorsfor pages 7-9) | | Translational — Dextromethorphan–bupropion (AXS‑05) | NMDA antagonism + sigma‑1 agonism (dextromethorphan) combined with monoaminergic reuptake inhibition (bupropion) — designed for oral rapid efficacy in MDD. | SLC6A3 (bupropion target indirect), sigma‑1 receptor (SIGMAR1) | Cortical neurons; monoaminergic neurons | Prefrontal cortex | "modulation of synaptic transmission" | Dextromethorphan, bupropion (combination product Auvelity / AXS‑05) | Approved agent; cited as translational glutamatergic success in review of glutamatergic modulators (McIntyre & Jain, doi:10.1007/s40263-024-01114-y, 2024) (mcintyre2024glutamatergicmodulatorsfor pages 7-9) | | Translational — Neurosteroids (brexanolone; zuranolone) | Positive allosteric modulation of synaptic and extrasynaptic GABAA receptors (including δ‑subunit‑containing receptors) producing rapid mood stabilization, esp. postpartum depression. | GABRA4, GABRD, AKR1C1/2 (steroid metabolism enzymes) | Cortical/limbic neurons; astrocytes | Limbic system; postpartum systemic context | "GABAergic synaptic transmission" (GO:0032228) | Brexanolone (IV allopregnanolone), Zuranolone (oral neurosteroid) | Neurosteroid drug reviews and clinical-update summaries (efficacy in PPD; zuranolone clinical meta‑analyses exist in 2023–24 literature); clinical trial summaries and mechanism reviews (correia2024advancementsexploringmajor pages 8-9, correia2024advancementsexploringmajor pages 1-2) (2023–2024) |

Table: Concise, citable table mapping core molecular/cellular pathways implicated in Major Depressive Disorder with representative genes, cell types, loci, GO processes, key chemicals/drugs, and recent 2023–2024 evidence (pqac citations). This aids rapid reference for mechanism-to-translation links.

Evidence items with URLs/dates (selection) - Cui L et al. Major depressive disorder: hypothesis, mechanism, prevention and treatment. Signal Transduct Target Ther. 2024; DOI: 10.1038/s41392-024-01738-y; URL: https://doi.org/10.1038/s41392-024-01738-y (Feb 2024) (cui2024majordepressivedisorder pages 23-24). - McIntyre RS, Jain R. Glutamatergic modulators for major depression from theory to clinical use. CNS Drugs. 2024; DOI: 10.1007/s40263-024-01114-y; URL: https://doi.org/10.1007/s40263-024-01114-y (Aug 2024) (mcintyre2024glutamatergicmodulatorsfor pages 7-9). - Kouba BR et al. Role of inflammatory mechanisms in major depressive disorder. Cells. 2024; DOI: 10.3390/cells13050423; URL: https://doi.org/10.3390/cells13050423 (Feb 2024) (kouba2024roleofinflammatory pages 2-3). - Correia AS, Vale N. Advancements exploring MDD: oxidative stress, serotonin, BDNF, HPA, pharmacotherapy. Int J Transl Med. 2024; DOI: 10.3390/ijtm4010010; URL: https://doi.org/10.3390/ijtm4010010 (Mar 2024) (correia2024advancementsexploringmajor pages 1-2). - Wetzel C et al. Mitochondrial and cellular function in patient‑derived cells in MDD. Int J Mol Sci. 2024; DOI: 10.3390/ijms25020963; URL: https://doi.org/10.3390/ijms25020963 (Jan 2024) (wetzel2024mitochondrialandcellular pages 10-12). - Zhang L et al. Multi‑omics insights in MDD: neuronal dysfunction (dlPFC). medRxiv. 2025; DOI: 10.1101/2025.05.03.25326369; URL: https://doi.org/10.1101/2025.05.03.25326369 (May 2025; preprint) (zhang2025multiomicsinsightsin pages 14-18).

Notes and limitations - While monoamine agents remain first‑line, recent evidence emphasizes convergent plasticity, immune, and bioenergetic mechanisms; the translational approvals of glutamatergic modulators and neurosteroids underscore the mechanistic shift (Cui 2024; McIntyre & Jain 2024) (cui2024majordepressivedisorder pages 23-24, mcintyre2024glutamatergicmodulatorsfor pages 7-9). - Quantitative effect sizes vary across agents and populations; mechanistic claims and implementation notes above derive from peer‑reviewed reviews and patient‑derived cell studies cited herein (mcintyre2024glutamatergicmodulatorsfor pages 7-9, wetzel2024mitochondrialandcellular pages 10-12).

Plan status: Completed literature identification; synthesized mechanistic domains; produced ontology mappings; summarized clinical implementations and embedded an evidence map. Further additions could include specialized biomarker prevalence estimates and circadian‑focused human studies as they emerge in 2024–2025 cohorts.

References

(cui2024majordepressivedisorder pages 23-24): Lulu Cui, Shu Li, Siman Wang, Xiafang Wu, Yingyu Liu, Weiyang Yu, Yijun Wang, Yong Tang, Maosheng Xia, and Baoman Li. Major depressive disorder: hypothesis, mechanism, prevention and treatment. Signal Transduction and Targeted Therapy, Feb 2024. URL: https://doi.org/10.1038/s41392-024-01738-y, doi:10.1038/s41392-024-01738-y. This article has 801 citations and is from a peer-reviewed journal.
(mcintyre2024glutamatergicmodulatorsfor pages 7-9): Roger S. McIntyre and Rakesh Jain. Glutamatergic modulators for major depression from theory to clinical use. CNS Drugs, 38:869-890, Aug 2024. URL: https://doi.org/10.1007/s40263-024-01114-y, doi:10.1007/s40263-024-01114-y. This article has 44 citations and is from a peer-reviewed journal.
(kouba2024roleofinflammatory pages 2-3): Bruna R. Kouba, Laura de Araujo Borba, Pedro Borges de Souza, Joana Gil-Mohapel, and Ana Lúcia S. Rodrigues. Role of inflammatory mechanisms in major depressive disorder: from etiology to potential pharmacological targets. Cells, 13:423, Feb 2024. URL: https://doi.org/10.3390/cells13050423, doi:10.3390/cells13050423. This article has 125 citations and is from a poor quality or predatory journal.
(correia2024advancementsexploringmajor pages 1-2): Ana Salomé Correia and Nuno Vale. Advancements exploring major depressive disorder: insights on oxidative stress, serotonin metabolism, bdnf, hpa axis dysfunction, and pharmacotherapy advances. International Journal of Translational Medicine, 4:176-196, Mar 2024. URL: https://doi.org/10.3390/ijtm4010010, doi:10.3390/ijtm4010010. This article has 29 citations.
(wetzel2024mitochondrialandcellular pages 10-12): Christian Wetzel, Iseline Cardon, Sonja Grobecker, Selin Kücükoktay, Stefanie Bader, Tatjana Jahner, Caroline Nothdurfter, Kevin-Thomas Koschitzki, Mark Berneburg, Heidi Stöhr, Bernhard Weber, Marcus Höring, Gerhard Liebisch, Frank Braun, Tanja Rothammer-Hampl, Markus Riemenschneider, Rainer Rupprecht, and Vladimir Milenkovic. Mitochondrial and cellular function in fibroblasts, induced neurons, and astrocytes derived from case study patients: insights into major depression as a mitochondria-associated disease. International Journal of Molecular Sciences, Jan 2024. URL: https://doi.org/10.3390/ijms25020963, doi:10.3390/ijms25020963. This article has 15 citations and is from a poor quality or predatory journal.
(zhang2025multiomicsinsightsin pages 14-18): Lingfeng Zhang, M. Lyu, Simeng Ma, M. D. Y. Xu, M. D. X. Xie, Qian Gong Ph. D., Lijun Kang M. D., Shijia Chen Ph. D., and Zhongchun Liu M. D. Multi-omics insights in major depressive disorder: dysfunction of neurons. MedRxiv, May 2025. URL: https://doi.org/10.1101/2025.05.03.25326369, doi:10.1101/2025.05.03.25326369. This article has 0 citations.
(correia2024advancementsexploringmajor pages 8-9): Ana Salomé Correia and Nuno Vale. Advancements exploring major depressive disorder: insights on oxidative stress, serotonin metabolism, bdnf, hpa axis dysfunction, and pharmacotherapy advances. International Journal of Translational Medicine, 4:176-196, Mar 2024. URL: https://doi.org/10.3390/ijtm4010010, doi:10.3390/ijtm4010010. This article has 29 citations.

Major Depressive Disorder

Ask OpenScientist

OpenScientist Report

Classifications

Subtypes

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Biochemical Markers

Source YAML

References & Deep Research

References

Deep Research

Disorder

Key Pathophysiology Nodes

Citation Inventory (for evidence mapping)